Literature DB >> 16739305

Nuclear size as prognostic determinant in stage II and stage III colorectal adenocarcinoma.

Abdelbaset Buhmeida1, Annika Algars, Raija Ristamäki, Yrjö Collan, Kari Syrjänen, Seppo Pyrhönen.   

Abstract

BACKGROUND: The prognostic value of morphometric nuclear features was assessed in stage II and stage III colorectal cancer (CRC).
MATERIALS AND METHODS: Primary tumors from 123 CRC patients were analyzed using an image overlay drawing system for the following nuclear size features: area, perimeter, diameter and form features.
RESULTS: The nuclear area (NA) was significantly different in tumors at different localizations (p=0.029). A large NA was a significant predictor of recurrent disease, with overall response (OR) 3.09 (1.37-6.95) (p =0.006). The NA was significantly larger in recurrent cases (106.3 microm2) than in non-recurrent ones (96.6 microm2) (p=0.007) and was a significant predictor of disease-free survival (DFS) in univariate (Kaplan-Meier) analysis (log-rank p=0.0239). However, lymph node involvement was the most powerful predictor of DFS in multivariate analysis, with OR 3.371 (95%CI 1.17-9.65) (p=0.024) and disease recurrence the only independent predictor of disease-specific survival (DSS), with OR 48.4 (95%CI 6.30-371.73).
CONCLUSION: Quantitative measurement of the NA seems to accurately discriminate the patients, among stage II and III colorectal cancer, who are likely to develop disease recurrence. Image morphometry seems to be a useful adjunct tool in examining the subgroup of lymph node-negative patients to predict the risk of disease recurrence and indications for adjuvant therapy.

Entities:  

Mesh:

Year:  2006        PMID: 16739305

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Development of on-chip multi-imaging flow cytometry for identification of imaging biomarkers of clustered circulating tumor cells.

Authors:  Hyonchol Kim; Hideyuki Terazono; Yoshiyasu Nakamura; Kazuko Sakai; Akihiro Hattori; Masao Odaka; Mathias Girault; Tokuzo Arao; Kazuto Nishio; Yohei Miyagi; Kenji Yasuda
Journal:  PLoS One       Date:  2014-08-20       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.